The Project SCYLLA (SARS-Cov-2 Large-scale Longitudinal Analyses) protocol has been finalized and is available here. SCYLLA’s objectives are to assess the comparative safety and effectiveness of all emerging drug therapies used in COVID-19 treatments …
… administered during hospitalization and prior to intensive services.
… administered during hospitalization after initiating intensive services.
… administered after COVID-19 positive testing and prior to hospitalization.
We believe this set of analyses could provide a critical impact in informing the overall effectiveness of various treatments being used globally against COVID-19. We have databases from 10 nations across Asia, Europe and North America, so we will be able to generate reliable real-world evidence at scale to inform decision-making around this pandemic and are seeking active participation from around the world. We continue to seek more collaborators to join in this important network study; any researchers with data in the OMOP CDM are encouraged to ‘join the journey.’
We have set up a specific thread on the forum seeking community feedback for the treatments and outcomes under investigation; you can find these in Appendix A & B of the protocol. Please use this thread for all feedback. Thank you!